

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

FORM 8-K

---

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report: September 29, 2017  
(Date of earliest event reported)

**CELLECTAR BIOSCIENCES, INC.**  
(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**1-36598**  
(Commission  
File Number)

**04-3321804**  
(IRS Employer  
Identification Number)

**3301 Agriculture Drive, Madison, Wisconsin 53716**  
(Address of principal executive offices)

**(608) 441-8120**  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

---

**ITEM 7.01      REGULATION FD DISCLOSURE**

On September 29, 2017, we issued a press release announcing that our President and Chief Executive Officer Jim Caruso will present and meet with investors at the MicroCap Conference on Thursday, October 5th at 12:30 PM ET at the Essex House in New York City. A copy of the press release is furnished as Exhibit 99.1 and is incorporated by reference herein.

**ITEM 9.01      FINANCIAL STATEMENTS AND EXHIBITS**

(d) Exhibits

| Number                      | Title                                                                                                                               |
|-----------------------------|-------------------------------------------------------------------------------------------------------------------------------------|
| <a href="#"><u>99.1</u></a> | <a href="#"><u>Press release dated September 29, 2017, titled “Collectar Biosciences to Present at the MicroCap Conference”</u></a> |

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: September 29, 2017

**CELLECTAR BIOSCIENCES, INC.**

By: /s/ John P. Hamill

Name: John P. Hamill

Title: Interim Chief Financial Officer

**Collectar Biosciences to Present at The MicroCap Conference**

Madison, Wis., (September 29, 2017) -- Collectar Biosciences, Inc. (Nasdaq: CLRB), an oncology-focused biotechnology company (the "company"), today announced that president and CEO Jim Caruso will present and meet with investors at The MicroCap Conference on Thursday, October 5<sup>th</sup> at 12:30 PM ET at The Essex House in New York City.

The live presentation will be webcast at <http://microcapconf.com/conferences/new-york-2-2017>, and archived on the company's website following the conference.

**About Collectar Biosciences, Inc.**

Collectar Biosciences (Nasdaq: CLRB) is developing phospholipid drug conjugates (PDCs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. Collectar's PDC platform is based on the company's proprietary phospholipid ether analogs. These novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers, even sites of metastases. The company's lead therapeutic PDC, CLR 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload. CLR 131 has been designated as an orphan drug by the US FDA and is currently being evaluated in a Phase 1 clinical study in patients with relapsed or refractory multiple myeloma and a Phase 2 clinical study to assess efficacy in a range of B-cell malignancies. The company is also developing proprietary PDCs for targeted delivery of chemotherapeutics and has several preclinical stage product candidates, and plans to expand its PDC chemotherapeutic pipeline through both in-house and collaborative R&D efforts. For more information please visit [www.collectar.com](http://www.collectar.com).

# # #

**Contact:**

Jules Abraham  
JQA Partners, Inc.  
917-885-7378  
[jabraham@jqapartners.com](mailto:jabraham@jqapartners.com)

---